Hauppauge, NY – August 1, 2016 – Cantel Medical Corporation subsidiary, Crosstex, continues its’ market diversification and expansion with the acquisition of Accutron Inc., the industry leading manufacturer of "conscious sedation" nitrous oxide delivery systems and nasal masks. Conscious sedation in dentistry is used to put the patient in a relaxed state during a dental procedure and is currently used in more than fifty percent of all dental practices and more than ninety percent of pediatric dental practices. Conscious sedation is safe and effective, induces a relaxed state, decreases anxiety and physical movement, and may eliminate the need for local anesthesia in certain instances. This allows the practitioner to deliver better patient care. All Accutron products are FDA compliant, carry the CE Mark, are registered with Health Canada and manufactured in their ISO 13485 facility in Phoenix, AZ.
"Conscious sedation and the safety and comfort of the patient have always been the focus of our company. From the very beginning we strived to be the market leader and market innovator in conscious sedation technology" stated Accutron Vice President of Sales & Marketing Jonathan Blasdell. He went on to state, "We firmly believe that by coming together as one and combining the strengths of the Crosstex marketing network, Accutron’s technology and manufacturing capabilities, and the continued utilization and professionalism of the PSA sales team, we can increase the understanding and expand the use of conscious sedation in dentistry."
Andrew Whitehead, Senior Vice President of Business Development stated, "Crosstex continues to diversify and expand its product portfolio and the markets it serves – all directly related to improving and enhancing the patient experience as it relates to infection prevention, patient safety and comfort. In the past 18 months we have acquired and become the market leader in dental unit waterlines with the acquisitions of DentaPure and Liquid Ultra, entered the industrial market with the acquisition of the NAMSA sterility assurance products division; and have now entered the small equipment/conscious sedation market with the acquisition of Accutron."
"With the strong support of our global distribution partners and our marketing/educational focus, we will elevate the awareness of conscious sedation as it relates to increased production for the dental practitioner as well as improving the patient experience in terms of infection prevention, safety and comfort." stated Gary Steinberg, President and CEO, Crosstex. "The addition of Accutron and their employees compliments our strategic vision. Their presence also
strengthens our relationship within the dental community, both domestically and internationally, bringing increased awareness to our existing portfolio of infection prevention, safety and compliance products."
Crosstex, a Cantel Medical company, manufactures a wide array of unique and innovative infection prevention and compliance products for the global healthcare industry. Founded in 1953 and headquartered in Hauppauge, New York, Crosstex is a recognized leader for its portfolio of waterline treatment, biological monitoring, sterility assurance packaging and personal protection equipment (PPE). Sold in more than 100 countries, the range of products distributed to medical, dental and veterinary practices and facilities include our award winning (5 consecutive years) Secure Fit technology face masks, DentaPure waterline treatment cartridges and Liquid Ultra, Sure-Check sterilization pouches with internal/external multi-parameter indicators, Tyvek pouches with 510K approval, SteamPlus Type 5 chemical integrators, ConFirm and Passport Plus in-office and mail-in biological indicators, Rapicide OPA/28 high level disinfectant.
For information on the full line of Crosstex infection prevention, patient safety and compliance products, please contact Crosstex at 631-582-6777 or visit www.crosstex.com.
About Cantel Medical Corp.
Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products, and specialty packaging for infectious and biological specimens. Additionally, we provide technical service for our products.
For further information, visit the Cantel website at www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.